Research News
Zoledronic acid prevents fractures in men with osteoporosis
Cite this as:
BMJ
2012;345:e7471
Zoledronic acid, a bisphosphonate given intravenously at a dose of 5 mg once a year, may reduce the risk of morphometric vertebral fractures in men by 67% compared with placebo. Morphometric fractures are identified by a change in shape of a bone, rather than from pain or other symptoms. About 40% of osteoporotic fractures in people over …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
Social bookmarking